ArticleFrontiers in immunology2025
TRIM29 drives ulcerative colitis by disrupting lipid metabolism via lysosomal dysfunction: a multi-omics and experimental study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicles from Li-Qi-Yang-Yin formula attenuate LPS-stimulated inflammatory injury in human colonic epithelial cellsFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pathogenesis of ulcerative colitis (UC) involves genetic susceptibility and immune dysregulation. However, a more comprehensive understanding of its underlying mechanisms is still required. Methods: Weighted correlation network analysis (WGCNA) and Mendelian randomization (MR) were used to investigate the association and causality between lipid metabolism and UC. Hub genes were identified by applying ensemble machine learning (LASSO, SVM, XGBoost) to the merged transcriptomic data, followed by cell-type-specific localization using public single-cell RNA-seq data from UC tissues. Pathophysiological relevance was confirmed in a DSS-induced colitis mouse model. The mechanistic role of the key hub gene was defined through knockdown LPS challenge in colonic epithelial cells, coupled with transcriptomic profiling. Results: Integrated WGCNA and MR analyses established a strong association between UC and lipid metabolic pathways, which was experimentally confirmed by marked intracellular lipid accumulation in UC models. Mechanistically, this dysregulation was traced to lysosomal dysfunction, a finding solidified by pharmacological modulation with Rapamycin (enhancer) and Chloroquine (inhibitor), which directly demonstrated that lysosomal activity governs lipid metabolic disturbance. Subsequent machine-learning-based feature selection from lysosome-related genes pinpointed TRIM29 as a central regulator. Functional and transcriptomic analyses together demonstrated that TRIM29 knockdown attenuates UC progression by rescuing the lysosome-lipid metabolism axis, as evidenced by restored lysosomal function, enhanced cytoskeletal transport, improved lipid catabolism, a resolved pro-inflammatory immune profile, and downregulated inflammatory signaling. Conclusion: This study identifies TRIM29 as a master regulator that drives UC progression by disrupting lysosomal function and reprogramming lipid metabolism. Our work delineates the TRIM29-lysosome-lipid metabolism axis, providing a mechanistic rationale for targeting TRIM29 as a promising therapeutic strategy in UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.